Thought Leadership | Fish & Richardson

Diversity, Equity & Inclusion

Pro Bono & Social Responsibility

Legal Operations

Legal Project Management

Knowledge Management

Legal Technology Services

Patent Litigation

Trademark, Copyright & Media Litigation

Trade Secret Litigation

Standard Essential Patents

Chancery & Corporate Governance

<p><em>Inter Partes </em>Review</p>

Post-Grant Review

<p><em>Ex Parte</em> Reexamination</p>

Supplemental Examination

Patent Prosecution

Strategic Patent Counseling & Opinions

Patent Portfolio Management

Unitary Patent & Unified Patent Court

IP Licensing, Transactions & Agreements

Trademark & Copyright Counseling & Prosecution

Strategic Counseling, Registration & Opinions

Advertising & Marketing

Domain Names & Internet

TTAB Oppositions & Cancellations

Digital Millennium Copyright Act

Transactions & Agreements

Regulatory & Government Affairs

Communications & Spectrum Regulation

Drug & Medical Device Regulation

mHealth & Telemedicine

Privacy & Data Security

Electrical & Computer Technology

Software & Internet

Consumer Electronics

Artificial Intelligence

Digital Media & E-Commerce

Financial, Business & FinTech Services

Telecommunications

Energy & Chemicals

Biotech & Diagnostics

Medical Devices

Pharmaceuticals

Academic Research & Medical Centers

Transportation, Aerospace & Defense

Autonomous Vehicles

Thought Leadership

IP Law Essentials

Post-Grant Annual Reports

Search results

Blog | July 18, 2014

AIA revisions to false marking statute not unconstitutional

Blog | June 23, 2014

Personal jurisdiction in ANDA cases after Daimler - Has the analysis changed?

Blog | June 04, 2014

MDPA approves smallest salable unit as base; allows lump sum agreements as evidence of running royalty

Blog | April 29, 2014

Today's Supreme Court decisions may impact NPE cases related to attorney fees

Blog | April 29, 2014

NDIll addresses EMVR, apportionment, unpatented items in royalty base, and price erosion

Blog | April 23, 2014

DDE denies SJ of no damages where plaintiff's expert had been excluded

Article | April 22, 2014

Understanding Legal Trends in the Life Sciences Industry

Article | March 07, 2014

Drug Labeling Games: Skinny Labels Getting an FDA Assist

Blog | February 28, 2014

Fed. Cir. Confirms De Novo Review of Claim Construction

Blog | February 21, 2014

No foreseeability exception to doctrine of equivalents

Blog | February 20, 2014

Inurement for 102(g)(2) Does Not Require the Inventor to Expressly Direct Another to Reduce His Invention to Practice

Blog | February 12, 2014

Hatch-Waxman safe harbor expansion continues